BELLICUM PHARMACEUTICALS, INC Quarterly Debt-to-equity in % from Q3 2015 to Q3 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Bellicum Pharmaceuticals, Inc quarterly Debt-to-equity history and growth rate from Q3 2015 to Q3 2023.
  • Bellicum Pharmaceuticals, Inc Debt-to-equity for the quarter ending September 30, 2023 was -25 %, a 163% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2023 -25 -64.4 -163% Sep 30, 2023
Q2 2023 -79.3 -161 -197% Jun 30, 2023
Q1 2023 139 -194 -58.4% Mar 31, 2023
Q4 2022 53.7 +522 Dec 31, 2022
Q3 2022 39.4 +250 Sep 30, 2022
Q2 2022 81.7 +286 Jun 30, 2022
Q1 2022 333 +546 Mar 31, 2022
Q4 2021 -469 -191 -68.8% Dec 31, 2021
Q3 2021 -211 +89.9 +29.9% Sep 30, 2021
Q2 2021 -205 +309 +60.2% Jun 30, 2021
Q1 2021 -213 +20K +99% Mar 31, 2021
Q4 2020 -278 -898 -145% Dec 31, 2020
Q3 2020 -301 -487 -262% Sep 30, 2020
Q2 2020 -513 -605 -662% Jun 30, 2020
Q1 2020 -20.3K -20.3K -31123% Mar 31, 2020
Q4 2019 621 +561 +931% Dec 31, 2019
Q3 2019 186 +129 +227% Sep 30, 2019
Q2 2019 91.4 +38 +71.2% Jun 30, 2019
Q1 2019 65.3 +14.7 +28.9% Mar 31, 2019
Q4 2018 60.2 +19.2 +46.8% Dec 31, 2018
Q3 2018 56.9 +20.2 +55.1% Sep 30, 2018
Q2 2018 53.4 +20.6 +63% Jun 30, 2018
Q1 2018 50.6 +22.9 +82.6% Mar 31, 2018
Q4 2017 41.1 +17.9 +77.1% Dec 31, 2017
Q3 2017 36.7 +21 +134% Sep 30, 2017
Q2 2017 32.8 +22.5 +220% Jun 30, 2017
Q1 2017 27.7 +21.3 +332% Mar 31, 2017
Q4 2016 23.2 +20.2 +668% Dec 31, 2016
Q3 2016 15.7 +13.4 +593% Sep 30, 2016
Q2 2016 10.2 Jun 30, 2016
Q1 2016 6.42 Mar 31, 2016
Q4 2015 3.02 Dec 31, 2015
Q3 2015 2.26 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.